1. Home
  2. OMER vs BSRR Comparison

OMER vs BSRR Comparison

Compare OMER & BSRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OMER
  • BSRR
  • Stock Information
  • Founded
  • OMER 1994
  • BSRR 1977
  • Country
  • OMER United States
  • BSRR United States
  • Employees
  • OMER N/A
  • BSRR N/A
  • Industry
  • OMER Biotechnology: Pharmaceutical Preparations
  • BSRR Major Banks
  • Sector
  • OMER Health Care
  • BSRR Finance
  • Exchange
  • OMER Nasdaq
  • BSRR Nasdaq
  • Market Cap
  • OMER 391.1M
  • BSRR 460.0M
  • IPO Year
  • OMER 2009
  • BSRR 1994
  • Fundamental
  • Price
  • OMER $6.75
  • BSRR $31.33
  • Analyst Decision
  • OMER Buy
  • BSRR Hold
  • Analyst Count
  • OMER 3
  • BSRR 2
  • Target Price
  • OMER $9.00
  • BSRR $29.00
  • AVG Volume (30 Days)
  • OMER 1.0M
  • BSRR 38.1K
  • Earning Date
  • OMER 11-13-2024
  • BSRR 10-21-2024
  • Dividend Yield
  • OMER N/A
  • BSRR 3.06%
  • EPS Growth
  • OMER N/A
  • BSRR 4.47
  • EPS
  • OMER N/A
  • BSRR 2.52
  • Revenue
  • OMER N/A
  • BSRR $143,689,000.00
  • Revenue This Year
  • OMER N/A
  • BSRR N/A
  • Revenue Next Year
  • OMER N/A
  • BSRR $2.75
  • P/E Ratio
  • OMER N/A
  • BSRR $12.45
  • Revenue Growth
  • OMER N/A
  • BSRR 4.68
  • 52 Week Low
  • OMER $1.49
  • BSRR $17.69
  • 52 Week High
  • OMER $7.51
  • BSRR $35.13
  • Technical
  • Relative Strength Index (RSI)
  • OMER 80.62
  • BSRR 55.33
  • Support Level
  • OMER $4.18
  • BSRR $27.43
  • Resistance Level
  • OMER $7.51
  • BSRR $33.55
  • Average True Range (ATR)
  • OMER 0.43
  • BSRR 1.18
  • MACD
  • OMER 0.24
  • BSRR 0.16
  • Stochastic Oscillator
  • OMER 78.29
  • BSRR 50.65

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

About BSRR Sierra Bancorp

Sierra Bancorp is a California-based bank holding company, which offers a range of retail and commercial banking services. it offers a wide range of deposit products and services for individuals and businesses including checking accounts, savings accounts, money market demand accounts, time deposits, retirement accounts, and sweep accounts. The company's lending activities cover real estate, commercial (including small business), mortgage warehouse, agricultural, and consumer loans, and also offers commercial construction loans and multifamily and agricultural credit facilities among other types of real estate loans.

Share on Social Networks: